Clinical Trials Logo

Lymphoma, Lymphoblastic clinical trials

View clinical trials related to Lymphoma, Lymphoblastic.

Filter by:
  • None
  • Page 1

NCT ID: NCT02396043 Recruiting - Clinical trials for Lymphoma, Lymphoblastic

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Start date: March 2015
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.

NCT ID: NCT00199030 Completed - Clinical trials for Lymphoma, Lymphoblastic

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

Start date: February 2004
Phase: Phase 2
Study type: Interventional

This study tests the effectivity and tolerability of treatment with alemtuzumab (MabCampath) in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma. In Arm A, patients with refractory relapse receive a 2 week treatment with MabCampath followed by remission evaluation. In case of insufficient response, treatment with cladribine is added. In Arm B, patients with molecular relapse (minimal residual disease) receive a 4 week treatment with MabCampath followed by remission evaluation. In both arms, treatment is continued in case of response for up to two months.

NCT ID: NCT00199017 Completed - Clinical trials for Lymphoma, Lymphoblastic

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Start date: April 2004
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.

NCT ID: NCT00186875 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Start date: November 2003
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: - To estimate the response rate for patients with refractory or relapsed ALL. - To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.